LONDON (Alliance News) - Synairgen PLC on Thursday said the Data Safety Monitoring Committee has completed its planned safety review of a clinical trial of therapeutic candidate, SNG001.
The drug discovery and development company said the committee did not identify any safety concerns for patients currently enrolled in the second part of the phase two clinical trial.
As a result, the committee has subsequently endorsed allowing patients with more severe chronic obstructive pulmonary disease to participate in the trial.
"We welcome this decision from the Data Safety Monitoring Committee, as it aids trial recruitment and enables us to dose patients who have a higher medical need," said Synairgen Chief Executive Richard Marsden.
"Chronic obstructive pulmonary disease exacerbations are the second most common cause of unplanned hospital admission in England, and we are pleased to have the opportunity to develop SNG001 to include these high-risk patients prior to potential hospitalisation," added Marsden.
Synairgen shares were trading 1.7% higher on Thursday at 15.00 pence each.
Synairgen (SNG)